A representative from Custics stated, "This study was conducted from January to November 2024 on 40 children aged 5 to 12. The research report concluded that ‘Hautuki is considered a safe product for long-term use.’"
CEO Kangil Lee emphasized, “We conducted this clinical study to ensure trust and safety in our product for our customers. We are pleased with the results and will continue to improve our products to provide even better solutions.”
He added, "This clinical research has strengthened consumer confidence in Hautuki, especially among those interested in growth support. We plan to continue further research and enhance product quality.”
